1. Rice LB. 2008; Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 197:1079–81. DOI:
10.1086/533452. PMID:
18419525.
Article
3. Jeong S, Jeon K, Lee N, Park MJ, Song W. 2024; Changing genotypic distribution, antimicrobial susceptibilities, and risk factors of urinary tract infection caused by carbapenemase-producing
Pseudomonas aeruginosa. Ann Lab Med. 44:38–46. DOI:
10.3343/alm.2024.44.1.38. PMID:
37665284. PMCID:
PMC10485864.
Article
4. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. 2018; Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 18:318–27. DOI:
10.1016/S1473-3099(17)30753-3. PMID:
29276051.
6. Kim N, Ko SY, Park SY, Kim SY, Lee DE, Kwon KT, et al. 2024; Clonal distribution and its association with the carbapenem resistance mechanisms of carbapenem-non-susceptible
Pseudomonas aeruginosa isolates from Korean hospitals. Ann Lab Med. 44:410–7. DOI:
10.3343/alm.2023.0369.
Article
7. Yoo JS, Yang JW, Kim HM, Byeon J, Kim HS, Yoo JI, et al. 2012; Dissemination of genetically related IMP-6-producing multidrug-resistant
Pseudomonas aeruginosa ST235 in South Korea. Int J Antimicrob Agents. 39:300–4. DOI:
10.1016/j.ijantimicag.2011.11.018. PMID:
22325122.
8. Choi YJ, Kim YA, Junglim K, Jeong SH, Shin JH, Shin KS, et al. 2023; Emergence of NDM-1-producing
Pseudomonas aeruginosa sequence type 773 clone: shift of carbapenemase molecular epidemiology and spread of 16S rRNA methylase genes in Korea. Ann Lab Med. 43:196–9. DOI:
10.3343/alm.2023.43.2.196. PMID:
36281514. PMCID:
PMC9618910.
Article